The introduction of nicotinamide being a nicotine alternative in e-cigarette and smokeless products represents a major regulatory problem to the FDA. Nicotinamide doesn't have nicotinic receptor agonist action and is understood to act as a sedative at superior dosages6. The promises created by Nicotine River, ECBlend, along with other vendors that